.alpha.-hederin, alpha-hederin, Pulsatilla saponin A, Rha-Ara-3beta-hederagenin

| Name | Alpha-Hederin | ||
| PubChem CID | 73296 | ||
| Molecular Weight | 751.0g/mol | ||
| Synonyms |
.alpha.-hederin, alpha-hederin, Pulsatilla saponin A, Rha-Ara-3beta-hederagenin |
||
| Formula | C₄₁H₆₆O₁₂ | ||
| SMILES | CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)CO)CCC5(C4CC=C6C5(CCC7(C6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O)O)O | ||
| InChI | 1S/C41H66O12/c1-21-28(44)30(46)31(47)33(51-21)53-32-29(45)24(43)19-50-34(32)52-27-11-12-37(4)25(38(27,5)20-42)10-13-40(7)26(37)9-8-22-23-18-36(2,3)14-16-41(23,35(48)49)17-15-39(22,40)6/h8,21,23-34,42-47H,9-20H2,1-7H3,(H,48,49)/t21-,23-,24-,25+,26+,27-,28-,29-,30+,31+,32+,33-,34-,37-,38-,39+,40+,41-/m0/s1 | ||
| InChIKey | KEOITPILCOILGM-LLJOFIFVSA-N | ||
| CAS Number | 27013-91-8 | ||
| ChEMBL ID | CHEMBL447565 | ||
| ChEBI ID | CHEBI:69370 | ||
| KEGG ID | C08954 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure |
Download
2D
MOL
3D
MOL
|
||
| Chineses Pinyin | ChangChunTeng | ||
| Use Part | Stem-leaf | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Araliaceae
-->Genus: Hedera
-->Species: Hedera nepalensis
|
||
| Pair Name | Alpha-Hederin, Carboplatin | |||
| Partner Name | Carboplatin | |||
| Disease Info | [ICD-11: 2B90.Z] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Phosphorylation | PIK3CA | hsa5290 |
| Up-regulation | Phosphorylation | AKT1 | hsa207 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Down-regulation | Expression | CCND1 | hsa595 | |
| In Vivo Model | The running experiment was designed to test the chemopreventive activity of α-hederin when used as an adjuvant to carboplatin in an experimental model of mouse colon hyperplasia induced by 1,2-dimethylhydrazine (DMH). Fifty male Swiss albino mice were classified into five groups: group (I): saline group, group (II): DMH-induced colon hyperplasia control group, group (III): DMH + carboplatin (5 mg/kg) group, group (IV): DMH + α-hederin (80 mg/kg) group, and group (V): DMH + carboplatin (5 mg/kg)+α-hederin (80 mg/kg) group. | |||
| Result | Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling | |||
| Pair Name | Alpha-Hederin, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Up-regulation | Expression | ROS1 | hsa6098 |
| Up-regulation | Expression | SQSTM1 | hsa8878 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 |
| NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1483 | |
| Result | Our findings suggest that α-Hed can increase the killing effect of Tax on NSCLC cells by promoting ROS accumulation, and that combining α-Hed with classical Tax represents a novel strategy for treating NSCLC. | |||
| Pair Name | Alpha-Hederin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2B72.Z] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->ROS accumulation | |||
| Gene Regulation | Up-regulation | Expression | ROS1 | hsa6098 |
| Down-regulation | Expression | MMP9 | hsa4318 | |
| Down-regulation | Expression | MMP2 | hsa4313 | |
| Down-regulation | Expression | BIRC5 | hsa332 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | APAF1 | hsa317 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| HGC-27 | Gastric carcinoma | Homo sapiens (Human) | CVCL_1279 | |
| MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens (Human) | CVCL_5334 | |
| In Vivo Model | The collected HGC-27 cells were washed in serum-free DMEM, suspended in 100 μl of PBS and subcutaneously implanted into the dorsal region of nude mice. | |||
| Result | α-Hederin enhances cisplatin-induced anti-tumour effects in GC both in vitro and in vivo by promoting the accumulation of ROS and decreasing MMP. Our data strongly suggested that α-Hederin is a promising candidate for intervention in gastric cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling. Toxicol Mech Methods. 2021 Feb;31(2):138-149. doi: 10.1080/15376516.2020.1849483. | Click |
| 2 | The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells. Int J Mol Sci. 2018 Oct 18;19(10):3221. doi: 10.3390/ijms19103221. | Click |
| 3 | Combining α-Hederin with cisplatin increases the apoptosis of gastric cancer in vivo and in vitro via mitochondrial related apoptosis pathway. Biomed Pharmacother. 2019 Dec;120:109477. doi: 10.1016/j.biopha.2019.109477. | Click |